von Tresckow, Julia http://orcid.org/0000-0001-5873-4603
Cramer, Paula
Robrecht, Sandra
Langerbeins, Petra
Fink, Anna-Maria
Al-Sawaf, Othman
Fürstenau, Moritz http://orcid.org/0000-0002-6593-0140
Illmer, Thomas
Klaproth, Holger
Tausch, Eugen
Ritgen, Matthias
Fischer, Kirsten
Wendtner, Clemens-Martin
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Böttcher, Sebastian http://orcid.org/0000-0002-3603-761X
Eichhorst, Barbara F.
Hallek, Michael
Funding for this research was provided by:
Roche
Janssen-Cilag, Germany
Article History
Received: 15 October 2021
Revised: 23 May 2022
Accepted: 9 June 2022
First Online: 25 June 2022
Competing interests
: JvT: honoraria (AbbVie, AstraZeneca, Janssen, Roche); research funding (Janssen, Roche); PC: consulting fees (AbbVie, Acerta, AstraZeneca), honoraria (AbbVie, AstraZeneca, Janssen, Roche), travel support (AbbVie, AstraZeneca, Gilead, Janssen, Roche), research support (AbbVie, AstraZeneca, BeiGene, Gilead, Janssen, Novartis/GSK, Roche); SR: nothing to disclose; PL: research funding (Janssen-Cilag), Consulting fees (Janssen-Cilag, AbbVie, Astra Zeneca), honoraria (Janssen-Cilag, AbbVie, Astra Zeneca), travel support (Janssen-Cilag, AbbVie, Astra Zeneca); AMF: Celgene (Research grant), AbbVie (Travel Support), Janssen (Advisory Board); OAS: Janssen (Personal fees, honoraria, research funding), Roche (Personal fees, honoraria, research funding), AbbVie (Personal fees, honoraria, research funding), BeiGene (Honoraria, research funding), AstraZeneca (Personal fees, honoraria), Gilead (Personal fees, honoraria); MF: nothing to disclose; TI: nothing to disclose; HK: nothing to disclose; ET: Consulting fees (Roche, Abbvie, Janssen), honoraria (Roche, Abbvie, Janssen), payment for expert testimony (Roche, Abbvie, Janssen), travel support (Janssen, AbbVie); MR: personal fees from Hoffman-La Roche (advisory board) and nonfinancial support from Celgene; KF: Honoraria (AbbVie, Roche), travel grants (Roche); CMW: Grants (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), consulting fees (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), honoraria (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), travel support (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca), Participation on a Data Safety Monitoring Board or Advisory Board (Hoffmann-La Roche, Cilag-Janssen, AbbVie, Gilead, AstraZeneca); KAK: Mundipharma, Roche, Janssen (Speaker’s bureau, Honoraria, Resarch support, Consulting); SS: Advisory board honoraria (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis), Research support (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis), Travel support (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis), Speaker fees (AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis); SB: Janssen (research support), honoraria (Roche, AbbVie, Norvatis, Becton Dickonson, Janssen, Astra Zeneca, Sanofi); BE: grants and personal fees (Janssen-Cilag, Roche, Abbvie and Gilead), personal fees (Novartis, Celgene, ArQule, AstraZeneca and Oxford Biomedica (UK)), grants (BeiGene); MH: personal fees and other (AbbVie, Celgene, Gilead Sciences, Janssen, Mundipharma, Pharmacyclics, Roche).